Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity market experienced a modest decline in Q1 2025, with the S&P 500 Index falling 4.27%, while bonds showed stability with the Bloomberg U.S. Aggregate Bond Index rising 2.78%. In the first quarter, Aristotle Atlantic’s Large Cap Growth Strategy delivered -9.55% gross of fees (-9.68% net of fees), outperforming the Russell 1000 Growth Index’s -9.97% return. Security selection led the portfolio to outperform in the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2025.
In its first-quarter 2025 investor letter, Aristotle Atlantic Large Cap Growth Strategy highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $7.93 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -16.33%, and its shares lost 19.95% of their value over the last 52 weeks. On April 23, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $50.16 per share.
Aristotle Atlantic Large Cap Growth Strategy stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2025 investor letter:
“Bio-Techne Corporation (NASDAQ:TECH) detracted from performance in the first quarter on fears around National Institutes of Health (NIH) funding concerns. The Trump administration announced caps on administrative costs for NIH-funded research projects, and this has resulted in fears of a slowdown in the academic and government segment. Bio-Techne has recently stated that its view is, worst case, a possible 50 basis point headwind to growth. Bio-Techne has shown positive momentum following a strong fiscal second quarter earnings report that included organic revenue growth of 9%.”
A cutting-edge laboratory with technicians in white coats studying a POC device.
Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the fourth quarter compared to 25 in the third quarter. In the second quarter of fiscal 2025, the company generated $297 million in revenues, up 9% year-over-year on both reported and organic basis. While we acknowledge the potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we covered Bio-Techne Corporation (NASDAQ:TECH) and shared the list of best gene therapy stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.